Feature | February 10, 2014

Interventional Cardiologist Redefines Value for Everyday Medical Practice

February 10, 2014 — Achieving real quality improvement and reducing costs means re-evaluating what constitutes value, according to a new paper e-published in the journal Catheterization and Cardiovascular Interventions (CCI). A new formula to define value, as presented in the paper, equates “real value” with appropriateness together with clinically defined outcomes and patient-expected outcomes relative to costs.
 
“Physicians are ready for new tools and strategies to improve patient care, and interventional cardiologists’ long-standing commitment to innovation and quality improvement have enabled us to propose a solution and kick-start its adoption,” said Peter L. Duffy, M.D., MMM, FSCAI, medical director of the cardiovascular service line at the Reid Heart Center/FirstHealth of the Carolinas, Pinehurst, N.C., and the paper’s author.
 
The Real Value Equation captures the Institute of Medicine’s (IOM) six dimensions of quality: care that is safe, effective, efficient, timely, patient-centered and equitable. It emphasizes how its application will help physicians provide better care by allowing them to customize care for individual patient’s needs while adhering to best practices, guidelines and appropriate use criteria (AUC). The lens through which interventional cardiologists can view decisions is based on the following four parameters:
 
  • The extent to which the benefit of the procedure outweighs the risk
  • The expected effect on the patient’s quality of life
  • How much the procedure reduces long- and short-term risk of complications
  • Whether the procedure will extend the patient’s life expectancy with the level of quality of life they expect
 
The author said focusing on AUC alone will not result in better population-based outcomes and will not address long-standing concerns regarding patient-centered care and spiraling healthcare costs, however. He called for interventional cardiologists to integrate appropriateness with clinical outcomes, patient expectations and resource utilization into clinical practice. 
 
“With heart disease care accounting for more than 40 percent of every healthcare dollar spent in the United States, interventional cardiologists are at the forefront of the conversation about how to change health care,” Duffy said. “We have the ability to make changes in our practice that will lead the way to meaningful change in this new phase of healthcare reform. As the Real Value equation takes hold, the possibilities to apply it beyond cardiology to every field will only become clearer, which is truly exciting.”
 
The paper is titled “Real Value: A Strategy for Interventional Cardiologists to Lead Healthcare Reform.” 
 
For more information: www.SCAI.org

Related Content

A large subgroup analysis of the VOYAGER PAD randomized clinical trial showed neither a mortality risk nor benefit associated with the use of paclitaxel drug-coated devices (DCD) in the treatment of peripheral artery disease (PAD). The study also found that the benefit of rivaroxaban use on reducing ischemic limb and cardiovascular outcomes was consistent regardless of whether a DCD was used. #TCT2020 #TCTconnect
Feature | Cath Lab | October 18, 2020
October 18, 2020 – A large subgroup analysis of a randomized clinical trial showed neither a mortality risk nor benef
A longitudinal vessel assessment may demonstrate co-existence of multiple plaque morphologies on OCT, including superficial calcification with thrombus, healed plaque, plaque rupture, lipidic plaque with a thin capped fibrous atheroma (TCFA). #TCTconnect #TCT2020

A longitudinal vessel assessment may demonstrate co-existence of multiple plaque morphologies on OCT, including superficial calcification with thrombus, healed plaque, plaque rupture, lipidic plaque with a thin cap fibro-atheroma (TCFA).

News | Cath Lab | October 18, 2020
October 18, 2020 – Data from the...
The DISRUPT CAD III study showed intravascular lithoplasty from Shockwave Medical was effective in breaking up calcified coronary lesions. #TCT2-0

The DISRUPT CAD III study showed intravascular lithoplasty from Shockwave Medical was effective in breaking up calcified coronary lesions.

Feature | Cath Lab | October 16, 2020
October 15, 2020 — Shockwave Medical's Intravascular Lithotripsy (IVL) system to treat severely calcified coronary ar
Videos | Cath Lab | October 16, 2020
This is an example pf the Shockwave Medical Intravascular Lithotripsy (IVL) catheter system designed to break up heav
Videos | Cath Lab | July 15, 2020
Richard Botto, CVT, RCSA, chief cardiovascular technologist, division of cardiology, cardiac cath lab, offers an over
Videos | Cath Lab | July 13, 2020
The Vieussens’ arterial ring (VAR) is a connection between the conus artery and the left anterior descending (LAD) co
News | Cath Lab | July 06, 2020
July 6, 2020 — Black patients who undergo percutaneous coronary intervention (PCI) are at an increased risk for major
TCT cancels in-person meeting and goes virtual due to COVID-19
News | Cath Lab | May 27, 2020
May 27, 2020 — To ensure the health and safety of all attendees due to the ongoing COVID-19 (SARS-CoV-2) pandemic, th